원발성 장림프종의 세포형에 따른 임상양상 및 예후인자

B-cell lymphoma unclassified, with features intermediate between DLBCL and Burkitt lymphoma (DLBCL/BL). Expected BL finding Relative

• Phase II clinical trials of PI3Kδ inhibitor (idelalisib) showed dramatic response in patients with previously treated indolent non-hodgkin’s

The “Asset Allocation” portfolio assumes the following weights: 25% in the S&P 500, 10% in the Russell 2000, 15% in the MSCI EAFE, 5% in the MSCI EME, 25% in the

1 John Owen, Justification by Faith Alone, in The Works of John Owen, ed. John Bolt, trans. Scott Clark, "Do This and Live: Christ's Active Obedience as the

Median overall survival of 28 multiple myeloma patients treated with Cyclophosphamide-Prednisone combination regimens as a primary therapy was 115 weeks.. Median

In order to analyze thermal stability and capacity loss according to the temperature of the battery cell by applying different C-rate discharge and

In addition, the expression of REDD1 was increased when Huh7 cells were treated with PA, and overexpression of REDD1 affected cell survival and lipid

Objective: The purpose of this study was to analyze recent trend in incidence of basal cell carcinoma and squamous cell carcinoma in patients from the Gwangju City